Questcor Pharmaceuticals — Investor Presentation (August 2013)
29 slides from Questcor Pharmaceuticals's investor presentation, Aug 6, 2013
Slide 1: NASDAQ: QCOR August 2013
Exhibit 99.1 NASDAQ: QCOR August 2013 1
Slide 2: Safe Harbor Statement
Safe Harbor Statement Note: Except for the historical information contained herein, this press release contains forward-looking statements that have been made pursuant to the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future financial performanc
Slide 3: Questcor
Questcor A biopharmaceutical company focused on the treatment of patients with serious, difficult-to- treat autoimmune and inflammatory disorders 3
Slide 4: Investment Highlights
Investment Highlights Flagship product Acthar has a unique therapeutic role and sustainable competitive advantages Acthar is approved for 19 indications, many in markets with sizable unmet need Market penetration remains modest; sales increasing rapidly Increasing investment in R&D to create future
Slide 5: Q2-2013 Financial Results
Q2-2013 Financial Results Q2 –2013 Q2 –2012 Change Net Sales ($M) $184.6 $112.5 64% Net Sales ($M), Non-GAAP $196.1 $112.5 74% Fully Diluted, GAAP EPS $1.12 $0.65 72% Fully Diluted, Non-GAAP EPS $1.35 $0.69 96% Cash flow from operations ($M) $81.5 $43.2 89% Diluted shares outstanding 61.5 64.1 The r
Slide 6: Acthar
Acthar Flagship Product: • 19 approved indications Key Therapeutic Areas: • Nephrotic Syndrome, Multiple Sclerosis Relapse, Infantile Spasms, Rheumatology, Sarcoidosis • Significant areas of unmet need; large growth potential Strategy: • Expand awareness, appropriate use of Acthar in key specialties
Slide 7: Acthar Distribution by Indication
Acthar Distribution by Indication Other Rheumatology 2% 18% Nephrology 40% Infantile Spasms 10% Neurology 30% Based on Acthar Net Sales Note: Questcor sells Acthar to a distributor and does not have complete data with respect to end-use; allocation based on internal estimates (Q2 2013). 7
Slide 8: Nephrotic Syndrome (NS)
Nephrotic Syndrome (NS) • Characterized by excessive spilling of protein from the kidneys into the urine (proteinuria) • Caused by a number of underlying types of kidney disease (e.g., iMN, FSGS, IgA nephropathy) • Can result in end-stage renal disease (ESRD), dialysis, transplant • Significant unme
Slide 9: Multiple Sclerosis (MS) Relapse
Multiple Sclerosis (MS) Relapse • A neurodegenerative disease occurring in about 400,000 patients in the US (>100,000 relapses/year) • Relapses range from mild to severe and can cause a range of symptoms – Loss of sensation in the extremities – Loss of vision – Loss of ability to walk • Relapses hav
Slide 10: Rheumatology
Rheumatology • Rheumatology-related indications on the Acthar label* – Dermatomyositis/Polymyositis (DM/PM) – Systemic lupus erythematosus (Lupus) – Rheumatoid arthritis – Psoriatic arthritis • Each can pose a serious health risk if not adequately controlled • Some cases difficult to manage; Acthar
Slide 11: Dermatomyositis and Polymyositis (DM/PM)
Dermatomyositis and Polymyositis (DM/PM) • Inflammatory neuromuscular diseases that cause a loss of muscle strength and mass – Significant quality of life issues; some patients require walkers or wheelchairs Alternative – Can also cause significant lung impairment Needed – Patients can experience ac
Slide 12: Systemic Lupus Erythematosus (Lupus)
Systemic Lupus Erythematosus (Lupus) • Chronic autoimmune disorder that can effect virtually any area of the body – Patients can experience acute exacerbations (flares) Alternative • Commonly used lupus treatments Needed - Prednisone, plaquenil, methotrexate, ~63K mycophenolate, azathioprine, Benlys
Slide 13: Rheumatoid Arthritis (RA)
Rheumatoid Arthritis (RA) • Chronic autoimmune disorder that causes inflammation of the synovial joints – Can be debilitating and lead to join destruction Alternative – Patients can experience acute exacerbations (flares) Needed ~65K • Commonly used RA treatments - Prednisone, methotrexate, azathiop
Slide 14: Psoriatic Arthritis (PsA)
Psoriatic Arthritis (PsA) • Chronic autoimmune disorder manifesting as both arthritis and psoriasis – Patients have both skin and joint manifestations Alternative – Patient can experience acute exacerbations (flares) Needed ~45K • Commonly used PsA treatments - Prednisone, methotrexate, azathioprine
Slide 15: Sarcoidosis
Sarcoidosis • Symptomatic sarcoidosis involves inflammation and formation of nodules in multiple organs, most commonly the lungs • Sarcoidosis fits our commercial model – Difficult-to-treat autoimmune/inflammatory condition – Limited treatment options • Previous successes in neurology, nephrology, r
Slide 16: Infantile Spasms (IS)
Infantile Spasms (IS) • Devastating, ultra-rare form of childhood epilepsy • Can cause permanent developmental disabilities, increased mortality • Actharisoftenconsidered the “goldstandard”andis currentlyusedto treat 40-50%of ISpatients 16
Slide 17: Advancing Our Understanding of the Science of Acthar and Melanocortin Peptides
Advancing Our Understanding of the Science of Acthar and Melanocortin Peptides • One of 9 families of hormones produced by the pituitary, the “master gland” • Believed to modulate the immune system and associated inflammatory response through binding to melanocortin receptors • Activate up to 5 targ
Slide 18: Melanocortin Peptides Activate Up to Five Melancortin Receptors
Melanocortin Peptides Activate Up to Five Melancortin Receptors Acthar Acthar ar MC2R MC1R MC3R MC4R MC5R Adrenal cortical cells Immune cells, CNS cells, kidney cells, muscle cells, Corticosteroids many other cells Steroid-independent anti-inflammatory/immunomodulatory effects Effects on Direct effe
Slide 19: Acthar Mechanism of Action
Acthar Mechanism of Action Clinical observations: o Acthar has increased efficacy (>86% vs <30%) vs. corticosteroids in infantile spasms o Acthar has been used with success when steroids are ineffective in idiopathic nephrotic syndrome 1 (iMN, FSGS and IgA nephropathy) • Preclinical observations dem
Slide 20: Implications of Acthar and Other Melanocortins (Synacthen and new MCs)
Implications of Acthar and Other Melanocortins (Synacthen and new MCs) • We now believe Acthar and other melanocortins impact – Immune system – Inflammation – Some cell function – Homeostasis • Dozens of severe medical conditions may benefit from Acthar or other melanocortin therapeutics 20
Slide 21: Significantly Increasing Investment in R&D
Significantly Increasing Investment in R&D • Have funded or have approved funding for ~70 projects – Company sponsored pre-clinical and clinical studies – Independent physician sponsored studies • Gaining an understanding of the biological properties of Acthar – Specific biochemical pathways, cells,
Slide 22: Acthar: Ongoing Research in Approved Indications
Acthar: Ongoing Research in Approved Indications • Idiopathic Membranous Nephropathy – Phase 4 trial ongoing – Refractory, non-responsive, or have relapsed on standard therapies • Persistently Active Lupus – Phase 4 trial initiated 4Q 2012 – Daily Acthar administration over a 6-month period • Lupus
Slide 23: Acthar Label Enhancement Strategy
Acthar Label Enhancement Strategy • Diabetic Nephropathy – One of the most common causes of end-stage renal disease in the U.S. – Phase 2 IND trial; Approx 40% enrolled • Amyotrophic Lateral Sclerosis (ALS) – Fatal neurological disease caused by progressive loss of motor neurons in the brain and spi
Slide 24: Global Growth Strategy
Global Growth Strategy Near Term • Continue to develop knowledge about melanocortin peptide pharmacology and potential clinical benefits • Continue the commercial and scientific development programs related to on-label Acthar indications • Expand commercial effort internationally with Synacthen 24
Slide 25: Global Growth Strategy
Global Growth Strategy Mediumterm • Develop new Acthar indications in the U.S. • Develop Synacthen for the U.S. • Investigate/pursue Acthar approvals ex U.S. Longer Term • Develop new melanocortin therapeutics 25
Slide 26: Committed to Creating Long Term Value for Shareholders
Committed to Creating Long Term Value for Shareholders • Continued stewardship of Acthar – Identifying and expanding Acthar therapeutic role in existing and new indications • Demonstrated ability to execute • Long term investment in R&Ddoubled -- R&D spending in 2012 • Highly selective, strategic di
Slide 27: NASDAQ: QCOR August 2013
NASDAQOCOR August 2013 (\® QUESTCOR’ 2]
Slide 28: Reconciliation of Non-GAAP Adjusted Financial Disclosure
Reconciliation of Non-GAAP Adjusted Financial Disclosure Three Months Ended Six Months Ended June 30, June 30, 2013 2012 2013 2012 Adjusted net income $83,323 $44,244 $128,987 $84,514 Share-based compensation expense (1) (4,382) (2,521) (8,546) (4,054) Depreciation and amortization expense (2) (1,88
Slide 29: MCR Tissue/Cell expression Potential biologic activity
MCR Tissue/Cell expression Potential biologic activity Podocytes • Immunomodulation(including modulation of Renal Mesangial Cells antigen presentation; immune cell adhesion and Endothelial Cells (Glomerular, Tubular, trafficking; dampen autoimmunity; NF-Kß Vascular) sequestration) Macrophages, Monoc
Questcor Pharmaceuticals — Investor Presentation (August 2013) on 6ix